For the quarter ending 2025-10-31, PMCB has $55,976,469 in assets. $19,422,384 in debts. $15,406,017 in cash and cash equivalents.
| Balance Sheets | 2025-10-31 | 2025-07-31 | 2025-04-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 15,406,017 | 13,178,305 | 15,172,163 | |
| Marketable equity securities | 201,190 | 261,853 | 366,316 | |
| Warrant asset qcls - current | 1,912,000 | 820,000 | 2,917,000 | |
| Convertible note receivable femasys - current | 5,000,000 | 4,608,000 | 3,696,000 | |
| Prepaid expenses and other current assets | 503,147 | 238,180 | 223,759 | |
| Total current assets | 23,022,354 | 19,106,338 | 22,375,238 | |
| Intangible asset | 1,549,427 | 1,549,427 | 1,549,427 | |
| Investment in preferred stock qcls | 20,747,000 | 19,635,000 | 22,474,000 | |
| Warrant asset qcls - non current | 9,530,000 | 2,966,000 | 5,701,000 | |
| Warrant asset femasys | 1,120,000 | 1,846,000 | 3,061,000 | |
| Convertible note receivable femasys - non current | - | - | 0 | |
| Other assets | 7,688 | 7,688 | 7,688 | |
| Total other assets | 32,954,115 | 26,004,115 | 32,793,115 | |
| Total assets | 55,976,469 | 45,110,453 | 55,168,353 | |
| Accounts payable | 1,021,339 | 465,209 | 399,204 | |
| Accrued expenses | 520,656 | 595,656 | 2,515,080 | |
| Accrued series c dividends | 35,389 | - | 0 | |
| Total current liabilities | 1,577,384 | 1,060,865 | 2,914,284 | |
| Long-term portion of accrued expenses | 0 | 0 | 25,000 | |
| Warrant liabilities | 16,152,000 | 458,000 | 338,000 | |
| Derivative liabilities | 1,693,000 | - | 0 | |
| Total other liabilities | 17,845,000 | 458,000 | 363,000 | |
| Total liabilities | 19,422,384 | 1,518,865 | 3,277,284 | |
| Convertible preferred stock-Series BPreferred Stock | 0 | 0 | 0 | |
| Convertible preferred stock-Series CPreferred Stock | 901,996 | - | - | |
| Contingently redeemable warrants | 417,000 | - | - | |
| Total temporary equity | 1,318,996 | - | - | |
| Preferred stock value-Series APreferred Stock | 0 | 0 | 0 | |
| Preferred stock value | - | - | 0 | |
| Common stock authorized 200,000,000 shares, 0.0001 par value 21,672,095 shares issued and 6,795,779 shares outstanding as of october 31, 2025 and april 30, 2025, respectively | 2,167 | 2,167 | 2,167 | |
| Additional paid-in capital | 180,611,996 | 181,550,139 | 181,489,647 | |
| Accumulated deficit | -100,747,031 | -93,329,056 | -84,968,960 | |
| Treasury stock, at cost, 14,876,316 shares as of october 31, 2025, and april 30, 2025, respectively | 44,607,916 | 44,607,916 | 44,607,916 | |
| Accumulated other comprehensive loss | -24,127 | -23,746 | -23,869 | |
| Total stockholders equity | 35,235,089 | 43,591,588 | 51,891,069 | |
| Total liabilities, temporary equity and stockholders equity | 55,976,469 | 45,110,453 | 55,168,353 | |
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)